Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 891 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
Regulatory Filings Classification · 15% confidence The document is a corporate press release announcing clinical trial topline results for a pharmaceutical product, with no substantive financial statements or reference to an investor presentation, earnings release, or other specific regulatory form. It is not an earnings release (ER), interim report (IR), or any form of financial or governance document. This type of general announcement falls under the catch-all Regulatory Filings category (RNS).
2026-05-21 English
Positiva topline-resultat från den pivotala fas 3-studien REDUCE 2 med pozdeutinurad vid gikt
Regulatory Filings Classification · 85% confidence The document is a press release (“Pressmeddelande”) from Sobi announcing topline phase 3 clinical trial results for pozdeutinurad (AR882). It contains no financial statements, earnings summaries, board changes, M&A details, or other specific categories. It is a regulated disclosure under EU market abuse rules but is essentially a general announcement of clinical study outcomes. This does not fit any specialized category (earnings release, interim report, M&A, etc.) and serves as a general market disclosure. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2026-05-21 Swedish
Bulletin from Sobi’s Annual General Meeting (AGM)
AGM Information Classification · 95% confidence The document is a press release dated 6 May 2026, titled 'Bulletin from Sobi’s Annual General Meeting (AGM)'. It details resolutions passed at the AGM, including adoption of financial statements, election of board members and auditors, approval of remuneration reports, long-term incentive programs, and authorizations related to share issuance and share transfers. The content is focused on the outcomes and decisions made during the AGM rather than the full annual report or financial statements themselves. The document length is 3966 characters, which is relatively short and consistent with an AGM information release rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2026-05-06 English
Kommuniké från Sobis årsstämma
AGM Information Classification · 95% confidence The document is a press release from Swedish Orphan Biovitrum AB (Sobi) dated May 6, 2026, reporting on the outcomes of the company's Annual General Meeting (AGM). It details shareholder decisions such as approval of financial statements, discharge of liability for the board and CEO, election of board members and auditors, approval of remuneration reports, long-term incentive programs, and authorization for share issuance. The content is typical of AGM information, summarizing resolutions passed at the meeting rather than providing full financial reports or detailed management analysis. The document length is 3657 characters, which is relatively short and consistent with an AGM information release rather than a full annual report or other detailed filings. Therefore, the appropriate classification is AGM Information (AGM-R).
2026-05-06 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport för första kvartalet 2026' which translates to 'Interim Report for the first quarter 2026'. It contains detailed financial data including revenues, EBITA, EPS, segment performance, and outlook for the year 2026. The text includes comprehensive financial tables, management commentary, and explanations of non-recurring items (IAC). The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content is consistent with a quarterly financial report providing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-28 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q1 2026 report' and contains detailed financial data for the first quarter of 2026, including revenue, EBITA, EPS, cash flow, and segment performance. It includes management commentary from the CEO, detailed tables with financial figures, and explanations of items affecting comparability. The content is comprehensive and covers a period shorter than a full fiscal year, with substantive financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR). The document is not a brief announcement or a certification, nor is it a full annual report or earnings release summary. Therefore, the appropriate classification is IR with high confidence. Q1 2026
2026-04-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.